Tenaya Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TNYA research report →
Range $2 – $3
Price Chart
About the company
Tenaya Therapeutics, Inc. , a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial.
- CEO
- Faraz Ali
- IPO
- 2021
- Employees
- 70
- HQ
- South San Francisco, CA, US
Get TickerSpark's AI analysis on TNYA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $65.32M
- P/E
- -0.60
- Fwd P/E
- 57.32
- PEG
- -0.01
- P/S
- 22.44
- P/B
- 1.24
- EV/EBITDA
- -0.04
- Div Yield
- 0.00%
- Gross Margin
- 172.06%
- Op Margin
- -3446.57%
- Net Margin
- -3356.79%
- ROE
- -115.21%
- ROIC
- -173.31%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-8,436,000+0.4%
- Op Income
- $-93,331,000
- Net Income
- $-90,597,000+18.5%
- EPS
- $-0.59+55.0%
- OCF Growth
- +24.6%
- FCF Growth
- +24.7%
- 52W High
- $1.46
- 52W Low
- $0.28
- 50D MA
- $0.48
- 200D MA
- $0.68
- Beta
- 2.88
- RSI (14)
- 28
- Avg Volume
- 2.91M
No earnings-call transcripts are available for TNYA yet.
- Free Float
- 94.5%
- Shares Outstanding
- 227.93M
- Float Shares
- 215.42M
of shares held by institutions
108 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 8.56M | ▲ 3.50M |
| Vanguard Capital Management LLC | 7.93M | ▲ 825.76K |
| Millennium Management LLC | 6.43M | ▲ 972.98K |
| Citadel Advisors LLC | 4.57M | ▲ 366.77K |
| Blackrock, Inc. | 4.20M | ▲ 191.20K |
| Empery Asset Management, LP | 3.86M | ▼ 423.82K |
| Renaissance Technologies LLC | 2.96M | ▼ 1.32M |
| Gsa Capital Partners Llp | 2.67M | ▲ 1.60M |
| Marshall Wace, Llp | 2.57M | ▼ 934.63K |
| Geode Capital Management, LLC | 2.20M | ▲ 366.22K |
| Burkehill Global Management, LP | 2.00M | 0 |
| Adar1 Capital Management, LLC | 1.56M | ▲ 47.70K |
Held by 41 ETFs
Biggest fund positions in TNYA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 17, 26 | Ali Faraz | sell | 3,499 |
| Nov 17, 26 | Tingley Whittemore | sell | 3,223 |
| Sep 10, 26 | Ali Faraz | other | 732,500 |
| Sep 10, 26 | Ali Faraz | other | 122,000 |
| Sep 10, 26 | Tingley Whittemore | other | 293,000 |
| Sep 10, 26 | Tingley Whittemore | other | 49,000 |
| Aug 17, 26 | Ali Faraz | sell | 5,837 |
| Aug 17, 26 | Ali Faraz | sell | 3,969 |
| Aug 17, 26 | Ali Faraz | sell | 5,020 |
| Aug 17, 26 | Ali Faraz | sell | 7,406 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our TNYA coverage
Recent articles, reports, and earnings notes.
No research on TNYA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TNYA report →Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Stock Now Rated “Moderate Buy” by Wall Street Brokerages
defenseworld.net · Nov 19
Tenaya Therapeutics, Inc. (TNYA) Reports Q3 Loss, Beats Revenue Estimates
zacks.com · Nov 4
Tenaya Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
globenewswire.com · Nov 4
Tenaya Therapeutics (NASDAQ:TNYA) and C4 Therapeutics (NASDAQ:CCCC) Financial Survey
defenseworld.net · Oct 22
Tenaya Therapeutics, Inc. (TNYA) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript
seekingalpha.com · Sep 17
Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
globenewswire.com · Sep 14
Tenaya Therapeutics to Participate in Upcoming September Investor Conferences
globenewswire.com · Sep 3
Tenaya Therapeutics Eyes Q4 Updates for Cardiac Gene Therapies, TN-301
marketbeat.com · Aug 18
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.